William Blair upgraded Inogen from Mkt Perform to Outperform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/16/2025 | $14.00 | Buy | B. Riley Securities |
| 5/22/2025 | $12.00 | Hold → Buy | Needham |
| 2/15/2024 | Mkt Perform → Outperform | William Blair | |
| 8/8/2023 | $15.00 → $8.00 | Overweight → Neutral | JP Morgan |
| 7/14/2023 | Buy → Hold | Needham | |
| 1/17/2023 | Outperform → Mkt Perform | William Blair | |
| 12/9/2021 | $47.00 | Hold → Buy | Needham |
| 11/8/2021 | $70.00 → $40.00 | Hold | Stifel |
B. Riley Securities initiated coverage of Inogen with a rating of Buy and set a new price target of $14.00
Needham upgraded Inogen from Hold to Buy and set a new price target of $12.00
William Blair upgraded Inogen from Mkt Perform to Outperform
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. On the same day, the Company will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen
Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. "Naga's deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership," said Kevin Smith, President and Chief Executive Officer of Inogen, "His ability to integrate software, data, and devices to improve user experiences will be instrume
Delivered strong top-line results; raising full year 2025 revenue expectations Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights Achieved second quarter 2025 revenue of $92.3 million, a year-over-year increase of 4.0%, marking the sixth consecutive quarter of mid-single-digit percentage growth. Reported GAAP net loss of $4.2 million and adjusted net loss of $0.7 million. Delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA. Generated $4.4 million in operating
10-Q - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
8-K - Inogen Inc (0001294133) (Filer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
4 - Inogen Inc (0001294133) (Issuer)
Inogen, Inc. (Nasdaq: INGN), a leading medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Naga Rameswamy as Chief Technology Officer, effective September 29, 2025. Mr. Rameswamy joins Inogen from Alcon, where he served as the Vice President and Global Head of Digital Health Platforms. "Naga's deep background in digital health and connected device innovation makes him an ideal fit for Inogen as we continue to expand our technology leadership," said Kevin Smith, President and Chief Executive Officer of Inogen, "His ability to integrate software, data, and devices to improve user experiences will be instrume
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Mira Kirti Sahney to Inogen's Board of Directors, effective January 31, 2025. The company also announced that Tom West, who has served as a director since April 2023, retired as a member of the Board of Directors, effective January 30, 2025. "We are thrilled to welcome Mira Sahney to the Inogen Board. Mira brings considerable management, technical, and operational experience in the medical device field to Inogen," said Elizabeth Mora, Chairperson of the Board. "Mira's appointment will further strengthen Inogen's Board with a
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025. On the same day, the Company will host a conference call at 5:30 a.m. PT / 8:30 a.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen
Delivered strong top-line results; raising full year 2025 revenue expectations Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced financial results for the quarter ended June 30, 2025. Recent Highlights Achieved second quarter 2025 revenue of $92.3 million, a year-over-year increase of 4.0%, marking the sixth consecutive quarter of mid-single-digit percentage growth. Reported GAAP net loss of $4.2 million and adjusted net loss of $0.7 million. Delivered adjusted EBITDA of $2.1 million, the second consecutive quarter of positive adjusted EBITDA. Generated $4.4 million in operating
Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it will report second quarter 2025 financial results after the market closes on Thursday, August 7, 2025. On the same day, the Company will host a conference call at 2:00 p.m. PT / 5:00 p.m. ET. Individuals interested in listening to the conference call may do so by dialing: US domestic callers (877) 841-3961 Non-US callers (201) 689-8589 Please reference Inogen to join the call. A live audio webcast and archived recording of the conference call will be available to all interested parties through the News / Events page on the Inogen I
SC 13G/A - Inogen Inc (0001294133) (Subject)
SC 13G - Inogen Inc (0001294133) (Subject)
SC 13G/A - Inogen Inc (0001294133) (Subject)